Search

Se buscó establecer la posible correlación de los análisis cefalométricos de Ricketts, Downs y Legan y determinar el grosor de tejidos blandos frente a caucásicos medidos en imágenes CBCT medinate un estudio cuantitativo no experimental relacional de corte transversal en adultos de 13 a 30 años residentes de la provincia de Azuay, esta investigación evaluó y analizo una muestra por conveniencia que estuvo constituida por 150 tomografías de cráneo completo que cumplieron los criterios de selección. Finalmente se determina que el análisis de Ricketts coincide en 107 casos con Downs y que esta correlación entre análisis no es completamente certera ya que los tejidos blandos buscan una compensación natural siendo en este caso mayormente pronunciados a nivel de mentón.

Objetivo: Registrar la densitometría ósea mediante CBCT en las zonas inter radiculares del maxilar superior para determinar cuál es la zona idónea para la colocación de microimplantes. Método: Estudio descriptivo observacional, incluyo a 103 tomografías, se realizaron diferentes cortes para determinar la densidad ósea de cada zona del área molar tomando como referencia 0.5 mm del borde inferior de la cresta alveolar y 0.6 mm de profundidad hacia la tabla ósea teniendo como referencia la menor longitud de un microtornillo ortodóntico. Resultados: es posible determinar que la zona con mayor densidad interradicular en el maxilar se presentó en el sexo femenino Z_7_D y zona menos densa Z_6_D, para el sexo masculino el área más densa es Z_4_D, mientras que la zona menos densa en los varones es la Z_7_I, por lo tanto, el área idónea para la colocación de microtornillos ortodónticos es la zona 4 (Z_4).

The aim of this study was to determine if low-dose dobutamine infusion can enhance Tc-99m methoxy isobutyl isonitrile (MIBI) uptake of hyperfunctioning parathyroid glands of patients with secondary hyperparathyroidism (SHP). We studied 24 patients with chronic renal failure and SHP. Median age of the sample was 47.5 years. A single-tracer, double-phase technique was performed, acquiring planar images of the neck and thorax after the injection of 740 to 1110 MBq (20-30 mCi) of Tc-99m MIBI. After 2 to 7 days, the study was repeated after the infusion of low-dose dobutamine of 2.0 microg . kg . min for 60 minutes. The scan was considered positive for hyperfunctioning parathyroid tissue when an area of increased uptake that persisted on late imaging was found. Parathyroid-to-thyroid count rates (PT/T) were calculated for each abnormal focus. Hyperplasic parathyroid tissue was confirmed in 12 of 24 patients who underwent neck surgery whereas the remaining group had persistent or worsening disease, verified by clinical follow-up between 6 and 25 months after the nuclear studies (median: 12 months). An MIBI baseline study was positive in 21 of 24 patients (87%), whereas the dobutamine study was positive in all patients. Thirty-five abnormal foci were seen on baseline MIBI studies and 43 on dobutamine scans (1.46 +/- 1.02 vs. 1.79 +/- 0.88, mean +/- SD, respectively, P = 0.043). Dobutamine PT/T ratios were significantly higher than those from the baseline study (1.49 +/- 0.30 vs. 1.38 +/- 0.28, mean +/- SD, respectively, P = 0.0002, n = 43). We concluded that low-dose dobutamine Tc-99m MIBI scintigraphy has the potential of enhancing tracer uptake and retention in patients with SHP.

Otosclerosis (OTSC) is one of the most common causes of hearing loss in white adults. The COL1A1 and COL1A2 genes coding for type-I collagen have been proposed as candidate genes in the development of OTSC. The COL1A1 gene was recently reported to be associated with the condition on the basis of a population-based case-control study. We report here an independent study of association between COL1A1 and COL1A2 gene polymorphisms and OTSC, in a case-control sample from a population of Caucasian individuals living in Northwest Spain. Specifically, we studied two COL1A1 polymorphisms previously reported to be associated with OTSC, and six COL1A2 polymorphisms. We performed diverse association analyses based on alleles, genotypes, and two-locus haplotypes. We found no evidence supporting the putative link of COL1A1 and COL1A2 genes with OTSC.

Disease status assessment of neuroblastoma patients requires computed tomography (or magnetic resonance imaging), bone scan, metaiodobenzylguanidine (MIBG) scan, bone marrow tests, and urine catecholamine measurements. There is no clinical experience concerning the evaluation of these patients by means of technetium-99m (99mTc)-somatostatin analog scintigraphy. Furthermore, these radiopharmaceuticals are promising imaging agents owing to their lower cost, availability, dosimetry, and ease of preparation. An 8-year-old boy already diagnosed with stage-IV neuroblastoma received chemotherapy. In the follow-up, after obtaining the parents’ informed consent, iodin 131 (131I)-MIBG and 99mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-octreotide scans were done on separate days to evaluate tumor extension. Even as the 131I-IBG scan showed mild diffuse uptake in the projection of both lung hili, the 99mTc-HYNIC-octreotide scan showed multiple axial and appendicular bone uptakes and paravertebral, abdominal, mediastinal, and supraclavicular ganglionar uptakes. The 99mTc-HYNIC-octreotide showed much more lesion extension than the 131I-MIBG. Therefore, 99mTc-HYNIC-octreotide may be a promising radiopharmaceutical for the evaluation of neuroblastoma patients. This finding justifies the pre liminary evaluation of this tracer in the context of a clinical trial.

Otosclerosis (OTSC) is one of the most common causes of hearing loss in white adults. The COL1A1 and COL1A2 genes coding for type-I collagen have been proposed as candidate genes in the development of OTSC. The COL1A1 gene was recently reported to be associated with the condition on the basis of a population-based case-control study. We report here an independent study of association between COL1A1 and COL1A2 gene polymorphisms and OTSC, in a case-control sample from a population of Caucasian individuals living in Northwest Spain. Specifically, we studied two COL1A1 polymorphisms previously reported to be associated with OTSC, and six COL1A2 polymorphisms. We performed diverse association analyses based on alleles, genotypes, and two-locus haplotypes. We found no evidence supporting the putative link of COL1A1 and COL1A2 genes with OTSC.

BACKGROUND: A study for pain relief therapy with 188Re-HEDP was done in patients with bone metastases secondary to breast and prostate cancer. MATERIALS AND METHODS: Patients received 1.3 or 2.2 GBq, in single or multiple doses. Platelets, white and red cells were evaluated during 11 weeks. Pharmacokinetic characterization was done from blood and urine samples for 5 patients along 24 hours. Urinary excretion was evaluated in other 16 patients during 6 hours. Bone uptake was estimated as remaining activity in whole body. Scintigraphic images were acquired at 2 and 24 hs post-administration. Absorbed dose in bone marrow was estimated with Mirdose3. Analgesics intake and pain score were daily recorded. Tumour markers (PSA, and Tn-structure) were monitored in 9 patients during 4 to 6 months. Single doses of low activity (1.3 GBq) were given to twelve patients. Nine patients received multiple doses. RESULTS: All except one patient had normal levels of platelets, white and red cells. Remaining dose in blood at 2 hours was 9%. Urinary elimination was 58%. Bone uptake at 24 hours was 43% (mean value; n = 5). No changes of the haematological parameters were detected along follow-up period. Pain relief was evidenced by decrease or supression of opioid analgesic and by subjective index. PSA showed a decrease in prostate cancer patients (n = 4). Tn-structure showed a significant increase after 4 to 8 months. CONCLUSION: Single or multiple dose scheme could be safely used, with administered activity of 188Re-HEDP up to 60 mCi, with low bone marrow absorbed doses.